Abstract
Background The study aimed to analyze the demographic, comorbidities, biomarkers, pharmacotherapy, and ICU-stay with the mortality outcome of COVID-19 patients admitted in the intensive care unit of a tertiary care hospital in a low-middle income country, Bangladesh.
Methods The retrospective cohort study was done in Holy Family Red Crescent Medical College Hospital from May to September 2020. All 112 patients who were admitted to ICU as COVID-19 cases (confirmed by RT-PCR of the nasopharyngeal swab) were included in the study. Demographic data, laboratory reports of predictive biomarkers, treatment schedule, and duration of ICU-stay of 99 patients were available and obtained from hospital records (non-electronic) and treatment sheets, and compared between the survived and deceased patients.
Results Out of 99 patients admitted in ICU with COVID-19, 72 were male and 27 were female. The mean age was 61.08 years. Most of the ICU patients were in the 60 - 69 years of age group and the highest mortality rates (35.89%) were observed in this age range. Diabetes mellitus and hypertension were the predominant comorbidities in the deceased group of patients. A significant difference was observed in neutrophil count, creatinine and, NLR, d-NLR levels that raised in deceased patients. There was no significant difference as a survival outcome of antiviral drugs remdesivir or favipiravir, while the use of cephalosporin was found much higher in the survived group than the deceased group (46.66% vs 20.51%) in ICU.
Conclusions Susceptibility to developing critical illness due to COVID-19 was found more in comorbid males aged more than 60 years. There were wide variations of the biomarkers in critical COVID-19 patients in a different population, which put the healthcare workers into far more challenge to minimize the mortality in ICU in Bangladesh and around the globe during the peak of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the designated hospital authority and the Institutional Ethics Review Board of Holy Family Red Crescent Medical College. The approval number: IERB/32/Res/Oct/2020/19/hf. Institutional Ethics review board members: 1. Prof.Maj.Gen(Rtd)H.R Harun Principal and Head of Urology 2. Brig.Gen.Shahadat Hossain Khan Director of Hospital 3. Prof. Md. Daulatuzzaman Professor of Otolaryngology 4. Prof. Ahmed Sayed Head of Surgery 5. Prof. Khaleda Akhter Head of Biochemistry 6. Prof. Abu Hena Mostofa Kamal Head of Medicine 7. Prof. Shahin Rahman Chowdhury Head of Obs & Gynaecology 8. Prof. Sabena Shahnaz Head of Microbiology This study protocol was approved by the IERB for use of the data and linkage. All necessary patient/participant consent has been waived as a retrospective (record based) study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: morshednasir{at}hotmail.com, morshed{at}hfrcmc.edu.bd
Email: rawshanperveen{at}gmail.com
Email: rumana.nazneen{at}gmail.com
Email: tahminazahan{at}yahoo.com
Email: sonianasreen{at}gmail.com
Email: saber.ac4321{at}gmail.com
Data Availability
All data are available on request
